3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invent...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Porter Roderick Alan Lord Christopher James Hopkins Anna Jarvis Ashley Nicholas Niculescu-Duvaz Dan Ashworth Alan Boffey Raymond John Key Rebekah Elisabeth Firth-Clark Stuart Skone Philip Alan Elliott Richard James Rowland Perrior Trevor Robert Bayford Melanie Jayne Aqil Rehan |
| description | The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US9611223B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US9611223B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US9611223B23</originalsourceid><addsrcrecordid>eNqNyjEKAjEQQNE0FqLeIReYIlkUbF0UsVXrJSYjBuIkZmYKby-CB7D5r_lzcxog9HeBNbDeWLKoYILM9aWZaskEDiqhjfXZqlJiGyhZeWDu3_bQUCVHq4xLM7uHwrj6uTD2sL-MR8BWJ-QWIhLKdD1vN855P-z88MfyAaodNMA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use</title><source>esp@cenet</source><creator>Porter Roderick Alan ; Lord Christopher James ; Hopkins Anna ; Jarvis Ashley Nicholas ; Niculescu-Duvaz Dan ; Ashworth Alan ; Boffey Raymond John ; Key Rebekah Elisabeth ; Firth-Clark Stuart ; Skone Philip Alan ; Elliott Richard James Rowland ; Perrior Trevor Robert ; Bayford Melanie Jayne ; Aqil Rehan</creator><creatorcontrib>Porter Roderick Alan ; Lord Christopher James ; Hopkins Anna ; Jarvis Ashley Nicholas ; Niculescu-Duvaz Dan ; Ashworth Alan ; Boffey Raymond John ; Key Rebekah Elisabeth ; Firth-Clark Stuart ; Skone Philip Alan ; Elliott Richard James Rowland ; Perrior Trevor Robert ; Bayford Melanie Jayne ; Aqil Rehan</creatorcontrib><description>The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.</description><language>eng</language><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS ; ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM ; CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; METALLURGY ; ORGANIC CHEMISTRY</subject><creationdate>2017</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170404&DB=EPODOC&CC=US&NR=9611223B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,782,887,25573,76557</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170404&DB=EPODOC&CC=US&NR=9611223B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Porter Roderick Alan</creatorcontrib><creatorcontrib>Lord Christopher James</creatorcontrib><creatorcontrib>Hopkins Anna</creatorcontrib><creatorcontrib>Jarvis Ashley Nicholas</creatorcontrib><creatorcontrib>Niculescu-Duvaz Dan</creatorcontrib><creatorcontrib>Ashworth Alan</creatorcontrib><creatorcontrib>Boffey Raymond John</creatorcontrib><creatorcontrib>Key Rebekah Elisabeth</creatorcontrib><creatorcontrib>Firth-Clark Stuart</creatorcontrib><creatorcontrib>Skone Philip Alan</creatorcontrib><creatorcontrib>Elliott Richard James Rowland</creatorcontrib><creatorcontrib>Perrior Trevor Robert</creatorcontrib><creatorcontrib>Bayford Melanie Jayne</creatorcontrib><creatorcontrib>Aqil Rehan</creatorcontrib><title>3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use</title><description>The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.</description><subject>ACYCLIC OR CARBOCYCLIC COMPOUNDS</subject><subject>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</subject><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2017</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyjEKAjEQQNE0FqLeIReYIlkUbF0UsVXrJSYjBuIkZmYKby-CB7D5r_lzcxog9HeBNbDeWLKoYILM9aWZaskEDiqhjfXZqlJiGyhZeWDu3_bQUCVHq4xLM7uHwrj6uTD2sL-MR8BWJ-QWIhLKdD1vN855P-z88MfyAaodNMA</recordid><startdate>20170404</startdate><enddate>20170404</enddate><creator>Porter Roderick Alan</creator><creator>Lord Christopher James</creator><creator>Hopkins Anna</creator><creator>Jarvis Ashley Nicholas</creator><creator>Niculescu-Duvaz Dan</creator><creator>Ashworth Alan</creator><creator>Boffey Raymond John</creator><creator>Key Rebekah Elisabeth</creator><creator>Firth-Clark Stuart</creator><creator>Skone Philip Alan</creator><creator>Elliott Richard James Rowland</creator><creator>Perrior Trevor Robert</creator><creator>Bayford Melanie Jayne</creator><creator>Aqil Rehan</creator><scope>EVB</scope></search><sort><creationdate>20170404</creationdate><title>3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use</title><author>Porter Roderick Alan ; Lord Christopher James ; Hopkins Anna ; Jarvis Ashley Nicholas ; Niculescu-Duvaz Dan ; Ashworth Alan ; Boffey Raymond John ; Key Rebekah Elisabeth ; Firth-Clark Stuart ; Skone Philip Alan ; Elliott Richard James Rowland ; Perrior Trevor Robert ; Bayford Melanie Jayne ; Aqil Rehan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US9611223B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2017</creationdate><topic>ACYCLIC OR CARBOCYCLIC COMPOUNDS</topic><topic>ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM</topic><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><toplevel>online_resources</toplevel><creatorcontrib>Porter Roderick Alan</creatorcontrib><creatorcontrib>Lord Christopher James</creatorcontrib><creatorcontrib>Hopkins Anna</creatorcontrib><creatorcontrib>Jarvis Ashley Nicholas</creatorcontrib><creatorcontrib>Niculescu-Duvaz Dan</creatorcontrib><creatorcontrib>Ashworth Alan</creatorcontrib><creatorcontrib>Boffey Raymond John</creatorcontrib><creatorcontrib>Key Rebekah Elisabeth</creatorcontrib><creatorcontrib>Firth-Clark Stuart</creatorcontrib><creatorcontrib>Skone Philip Alan</creatorcontrib><creatorcontrib>Elliott Richard James Rowland</creatorcontrib><creatorcontrib>Perrior Trevor Robert</creatorcontrib><creatorcontrib>Bayford Melanie Jayne</creatorcontrib><creatorcontrib>Aqil Rehan</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Porter Roderick Alan</au><au>Lord Christopher James</au><au>Hopkins Anna</au><au>Jarvis Ashley Nicholas</au><au>Niculescu-Duvaz Dan</au><au>Ashworth Alan</au><au>Boffey Raymond John</au><au>Key Rebekah Elisabeth</au><au>Firth-Clark Stuart</au><au>Skone Philip Alan</au><au>Elliott Richard James Rowland</au><au>Perrior Trevor Robert</au><au>Bayford Melanie Jayne</au><au>Aqil Rehan</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use</title><date>2017-04-04</date><risdate>2017</risdate><abstract>The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2/-/-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US9611223B2 |
| source | esp@cenet |
| subjects | ACYCLIC OR CARBOCYCLIC COMPOUNDS ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HETEROCYCLIC COMPOUNDS METALLURGY ORGANIC CHEMISTRY |
| title | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-30T01%3A41%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Porter%20Roderick%20Alan&rft.date=2017-04-04&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS9611223B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |